Overview

Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.

Status:
Unknown status

Trial end date:
2018-12-01

Target enrollment:

Participant gender:

Summary

This is a randomized, multicentre, Phase 3 study. Patients will be randomly assigned to the Study drug or its comparator. The study will be blinded for the staff members in charge of the endpoint assessment.

Phase:

Phase 3

Details

Lead Sponsor:

Gema Biotech S.A.

Collaborator:

QUID Quality in Drugs and Devices Latin American Consulting SRL

Treatments:

Lenograstim